<DOC>
	<DOCNO>NCT01778062</DOCNO>
	<brief_summary>This clinical study ass efficacy safety indacaterol ( 150㎍ o.d . ) patient Chronic Obstructive Pulmonary Disease ( COPD ) destroy lung tuberculosis .</brief_summary>
	<brief_title>Indacaterol EfectIveness In COPD Patients With Tuberculosis History</brief_title>
	<detailed_description>There clinical study patient COPD destroy lung tuberculosis tuberculosis patient usually exclude ( phase II III ) clinical trial drug registration although prohibit prescription COPD drug . This clinical study ass efficacy safety indacaterol ( 150㎍ o.d . ) patient COPD destroy lung tuberculosis .</detailed_description>
	<mesh_term>Tuberculosis</mesh_term>
	<criteria>Male female adult age ≥ 19 year international age Patients diagnosis moderatetosevere COPD classify GOLD guideline ( 2009 ) Patients least one finding destruct pulmonary parenchyma chest Xray sum legion volume equivalent 1/3 one lung Patients history tuberculosis change chest image test past one year Patients voluntarily sign Informed Consent Form prior initiation studyrelated procedure Pregnant nursing ( lactate ) woman Women childbearing potential willing use effective contraception . However , negative pregnancy test agree use effective contraception participate . Effective contraception include periodical abstinence ( e.g . basal body temperature , menstrual cycle contraceptive method , etc ) mean use contraception must include one barrier contraceptive method . e.g . ) condom ( barrier contraceptive method ) , diaphragm ( barrier contraceptive method ) , oral contraceptive , intrauterine device , Depo injection , etc . Patients admit hospital COPD worsening within 6 week prior visit 1 Patients history respiratory infection within 6 week prior visit 1 Patients require longterm oxygen therapy ( &gt; 15 hours/1 day ) chronic hypoxemia ( allow use total 10 24 hour PRN basis ) Patients history asthma Unstable ischaemic heart disease , arrhythmia ( except stable ventricular fibrillation ) uncontrolled hypertension Patients history long QT syndrome whose QTc interval measure Visit 2 prolong : &gt; 450 m ( male ) &gt; 470 m ( female ) Uncontrolled hypothyroidism hyperthyroidism Hypokalemia : plasma potassium level &lt; 3.0 mEq/L Patients creatinine level ≥2 upper limit normal Patients AST/ALT level ≥2 upper limit normal Patients lung cancer history lung cancer Patients active cancer history cancer le 5 year diseasefree survival ( whether evidence local recurrence metastasis ; localize basal cell carcinoma skin without metastasis acceptable ) . Patients history hypersensitivity study drug drug similar chemical structure include untoward reaction sympathomimetic amine inhale medication component thereof . Patients live attenuated vaccination within 30 day prior Visit 1 Patients treatment investigational drug , within 30 day 5 halflives prior Visit 1 , whichever longer . Patients unable successfully use dry powder inhaler device , meter dose inhaler perform spirometry measurements Other case consider ineligible clinical study principal investigator subinvestigator</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
</DOC>